SB
PTLA

Suntrust Banks’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Suntrust Banks’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-29,407
Closed -$760K – 1766
2014
Q1 		$760K Buy
+29,407
New +$785K ﹤0.01% 1106

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Suntrust Banks's PTLA Position: Q2 2014 in Review

Suntrust Banks sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2014, closing a stake of 29,407 shares — an estimated $760K sold.

Suntrust Banks first reported a position in PTLA in Q1 2014 and held it in 1 quarter. The position peaked at $760K in Q1 2014. 110 funds tracked by Wall St. Rank hold PTLA as of Q2 2014.

  • Suntrust Banks reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Suntrust Banks sold 29,407 Portola Pharmaceuticals, Inc. shares in Q2 2014, an estimated $760K.
  • Suntrust Banks first reported a position in Portola Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • Suntrust Banks's Portola Pharmaceuticals, Inc. position peaked at $760K in Q1 2014.
  • 110 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2014.

Based on Suntrust Banks's 13F filing for Q2 2014, filed 14 Aug 2014.